Cargando…

Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer

Conditionally replicating adenoviruses (CRAds) utilize tissue specific promoters to control the expression of the early genes, E1A and E1B, to preferentially replicate and lyse tumor cells (oncolysis). Previous CRAds used in prostate cancer gene therapy require androgens to activate prostate specifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Tamara Jane, Hoti, Naser Uddin, Liu, Chunyan, Chowdhury, Wasim H., Li, Ying, Zhang, Yonggang, Lupold, Shawn E., DeWeese, Theodore, Rodriguez, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732197/ https://www.ncbi.nlm.nih.gov/pubmed/23764901 http://dx.doi.org/10.1038/cgt.2013.34

Ejemplares similares

Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production
por: Höti, Naseruddin, et al.
Publicado: (2018)

A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation
por: Hatano, Koji, et al.
Publicado: (2015)

A novel method for generating and screening peptides and libraries displayed on adenovirus fiber
por: Lupold, Shawn E., et al.
Publicado: (2007)

A Real Time Metridia Luciferase Based Non-Invasive Reporter Assay of Mammalian Cell Viability and Cytotoxicity via the β-actin Promoter and Enhancer
por: Lupold, Shawn E., et al.
Publicado: (2012)

Oncolytic adenovirus-mediated therapy for prostate cancer
por: Sweeney, Katrina, et al.
Publicado: (2016)

Mechanism of Growth Inhibition of Prostate Cancer Xenografts by Valproic Acid
por: Sidana, Abhinav, et al.
Publicado: (2012)

Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer
por: Yang, Kaiyi, et al.
Publicado: (2022)

Does Valproic Acid Induce Neuroendocrine Differentiation in Prostate Cancer?
por: Sidana, Abhinav, et al.
Publicado: (2011)

Spectrophotometric Estimation of Bicalutamide in Tablets
por: Sancheti, P. P., et al.
Publicado: (2008)

Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)

Oncolytic Adenoviruses in Cancer Treatment
por: Alemany, Ramon
Publicado: (2014)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Concepts in Oncolytic Adenovirus Therapy
por: Mantwill, Klaus, et al.
Publicado: (2021)

A Renaissance for Oncolytic Adenoviruses?
por: Blanchette, Paola, et al.
Publicado: (2023)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
por: Kandil, Sahar B., et al.
Publicado: (2020)

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
por: Nguyen, Tien V, et al.
Publicado: (2018)

Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
por: Xie, Daoyuan, et al.
Publicado: (2023)

Targeting of mutant hogg1 in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress
por: Chatterjee, Aditi, et al.
Publicado: (2006)

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
por: Li, Yuezheng, et al.
Publicado: (2023)

Compression-Induced Phase Transitions of Bicalutamide
por: Szafraniec-Szczęsny, Joanna, et al.
Publicado: (2020)

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer
por: Mao, Li-jun, et al.
Publicado: (2018)

Confronting Racism in Radiation Oncology: Now Is the Time and Today Is the Day
por: DeWeese, Theodore L.
Publicado: (2020)

Increasing the Efficacy of Oncolytic Adenovirus Vectors
por: Toth, Karoly, et al.
Publicado: (2010)

Designer Oncolytic Adenovirus: Coming of Age
por: Baker, Alexander T., et al.
Publicado: (2018)

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
por: Zhao, Yaqi, et al.
Publicado: (2021)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Adenovirus as a Vector and Oncolytic Virus
por: Matsunaga, Wataru, et al.
Publicado: (2023)

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2015)

A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
por: Tian, Lei, et al.
Publicado: (2022)

Stability analysis on the radioactive iodine-labelled prostate cancer-specific recombinant oncolytic adenovirus
por: Zhou, Jiahe, et al.
Publicado: (2017)

Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation
por: Mao, Li-jun, et al.
Publicado: (2020)

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2019)

Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
por: Hajeri, Praveensingh B., et al.
Publicado: (2020)

Photoactivatable oncolytic adenovirus for optogenetic cancer therapy
por: Hagihara, Yasuko, et al.
Publicado: (2020)

Species D Adenoviruses as Oncolytic Viral Vectors
por: Bullard, Brianna L., et al.
Publicado: (2020)

Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
por: Hensen, Lobke C.M., et al.
Publicado: (2020)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f9sg28gku9jp011mvu66g1qv56